Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$1.63
+1.2%
$2.46
$0.55
$6.19
$126.18M3521,489 shs78,243 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$51.31
+1.7%
$32.41
$11.17
$52.87
$557.85M-0.01153,449 shs132,069 shs
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$8.68
$8.90
$4.62
$11.44
$543.54M0.263.63 million shsN/A
SNDL Inc. stock logo
SNDL
SNDL
$2.24
+1.4%
$1.55
$1.15
$2.40
$580.73M3.574.61 million shs2.37 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-5.29%-10.06%+8.78%+76.92%-20.30%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
+4.00%+12.99%+62.71%+128.13%+5,043,999,900.00%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
0.00%0.00%-3.23%+31.32%+3.95%
SNDL Inc. stock logo
SNDL
SNDL
+5.24%+3.27%+39.87%+68.70%+3.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
1.4147 of 5 stars
3.00.00.00.02.01.70.0
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2.8703 of 5 stars
3.50.00.00.02.92.50.6
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.4087 of 5 stars
2.05.00.04.10.61.70.6
SNDL Inc. stock logo
SNDL
SNDL
1.8376 of 5 stars
2.03.00.00.02.50.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
2.00
Hold$3.0084.05% Upside
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.09
Buy$58.5014.01% Upside
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
1.93
Reduce$7.85-9.56% Downside
SNDL Inc. stock logo
SNDL
SNDL
0.00
N/A$4.0078.57% Upside

Current Analyst Ratings Breakdown

Latest CTOR, PVLA, SAGE, and SNDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $66.00
8/15/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $75.00
8/15/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $60.00
8/5/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform$54.00
8/4/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$90.00
7/21/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$56.00
7/8/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.20
6/20/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.41 per shareN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M13.26N/AN/A$4.32 per share11.88
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$41.24M13.18N/AN/A$5.89 per share1.47
SNDL Inc. stock logo
SNDL
SNDL
$671.81M0.88N/AN/A$2.99 per share0.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/A0.00N/AN/A-51.93%-22.17%N/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%N/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%11/4/2025 (Estimated)
SNDL Inc. stock logo
SNDL
SNDL
-$69.18M-$0.27N/AN/AN/A-10.38%-8.58%-7.23%11/4/2025 (Estimated)

Latest CTOR, PVLA, SAGE, and SNDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$0.78-$0.86-$0.08-$0.86N/AN/A
7/31/2025Q2 2025
SNDL Inc. stock logo
SNDL
SNDL
-$0.04$0.01+$0.05$0.01$231.50 million$179.78 million
7/30/2025Q2 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.12
0.35
0.02
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
7.67
8.84
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
9.16
9.13
SNDL Inc. stock logo
SNDL
SNDL
0.11
5.03
3.36

Institutional Ownership

CompanyInstitutional Ownership
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
SNDL Inc. stock logo
SNDL
SNDL
N/A

Insider Ownership

CompanyInsider Ownership
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
4.57%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
20.50%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
SNDL Inc. stock logo
SNDL
SNDL
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A78.37 million74.79 millionN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A11.06 million8.79 millionN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million59.18 millionOptionable
SNDL Inc. stock logo
SNDL
SNDL
2,516262.78 millionN/AOptionable

Recent News About These Companies

SNDL (NASDAQ:SNDL) Trading 5.2% Higher - What's Next?
Form 13G SNDL Inc. For: 14 August
Traders Purchase Large Volume of Call Options on SNDL (NASDAQ:SNDL)
SNDL Inc. (SNDL) Q2 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$1.63 +0.02 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.06 (+3.37%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$51.31 +0.87 (+1.72%)
As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)
As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SNDL stock logo

SNDL NASDAQ:SNDL

$2.24 +0.03 (+1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$2.22 -0.02 (-0.67%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.